Credit: Insilico Medicine
Tuesday, June 25, 2019 – Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Ending Age-Related Diseases 2019 in New York, on July 11. Insilico Medicine is also very proud to be one of the sponsors of the event this year, which will give a unique opportunity to present our brand and to communicate with the most skilled people of ageing research. Ending Age-Related Diseases 2019 will take place in the heart of New York City at the Frederick P. Rose Auditorium, Cooper Union.
The biological aging clocks, using deep learning techniques, were first presented were first presented by the scientists at Insilico Medicine in 2015 and published in 2016. They can be used in a broad range of applications in the pharmaceutical industry, spanning target identification, drug discovery, data economics and synthetic patient data generation. The presentation will cover the applications of these aging clocks in actuarial science for prediction of mortality and health hazards.
Life Extension Advocacy Foundation has been very active at promoting research on aging around the world since its creation, and in 2018, hosted its own conference, in order to support the growth of the industry. This led to the creation of Ending Age-Related Diseases, a conference that brings together industry leaders of the ageing research for two action-packed days of biotechnology in the heart of New York City at the Cooper Union. The goal of this conference is to foster multidisciplinary collaboration in order to accelerate the development of next-generation drugs and therapies that directly target the processes of aging and thus have the potential to prevent and cure age-related diseases.
“As the global population is aging, morbidity from chronic age-related diseases is rapidly increasing. The drugs and therapies that could modify the way we age by addressing the root causes of aging would help us to prevent the onset of age-related diseases and extend the healthy period of life. However, in order to have these innovations developed in time, and to assess their effectiveness in the clinic, we need good methods of measuring biological aging. This is why we’ll begin the conference with a section on the biomarkers of aging before exploring advances in the fundamental studies of aging and discussing potential interventions. The list of confirmed speakers includes renowned researchers and visionaries, such as Aubrey de Grey (SENS Research Foundation), George Church (Harvard Medical School), Judith Campisi (the Buck Institute), Maria A. Blasco (CNIO), Ronald Kohanski (NIA), Morgan Levine (Yale Center for Research on Aging), Kelsey Moody (Ichor Therapeutics), Andrei Gudkov (Roswell Park Comprehensive Cancer Center), and many others,” said Elena Milova, LEAF Board Member and director of the conference
“We are happy to present our latest research at the Ending Age-related diseases 2019, which gathers the key scientists of the ageing research. The topic of biomarkers of ageing is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area,” said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine.
###
For further information, images or interviews, please contact:
Contact: Klug Gehilfe [email protected]
For press accreditation to the conference Ending Age-Related Diseases 2019, please contact Elena Milova [email protected]
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
Media Contact
Klug Gehilfe
[email protected]
